The inflammatory hypothesis of atherosclerosis postulates that inflammation within the plaque promotes plaque progression and complications. Interleukin-1 (IL-1) is a key pro-inflammatory cytokine responsible for the amplification of the inflammatory response following injury. Animal studies show that IL-1 blockade is effective in limiting atherosclerosis and atherothrombosis and improving outcomes in acute myocardial infarction and ischemic stroke. Preliminary data in patients with acute myocardial infarction, ischemic stroke, and heart failure are promising. A large secondary prevention trial with canakinumab in patients with prior acute myocardial infarction is currently ongoing. Many unanswered questions remain regarding the optimal use of IL-1 blockade and the preferred agent. © 2012 Springer International Publishing AG. All rights reserved.
Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events / Antonio, Abbate; Benjamin W., Van Tassell; BIONDI ZOCCAI, Giuseppe. - In: BIODRUGS. - ISSN 1173-8804. - 26:4(2012), pp. 217-233. [10.2165/11631570-000000000-00000]
Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events
BIONDI ZOCCAI, GIUSEPPE
2012
Abstract
The inflammatory hypothesis of atherosclerosis postulates that inflammation within the plaque promotes plaque progression and complications. Interleukin-1 (IL-1) is a key pro-inflammatory cytokine responsible for the amplification of the inflammatory response following injury. Animal studies show that IL-1 blockade is effective in limiting atherosclerosis and atherothrombosis and improving outcomes in acute myocardial infarction and ischemic stroke. Preliminary data in patients with acute myocardial infarction, ischemic stroke, and heart failure are promising. A large secondary prevention trial with canakinumab in patients with prior acute myocardial infarction is currently ongoing. Many unanswered questions remain regarding the optimal use of IL-1 blockade and the preferred agent. © 2012 Springer International Publishing AG. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.